{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:02:26Z","timestamp":1790841746162,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ejim.2026.107014","type":"journal-article","created":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:22:52Z","timestamp":1781954572000},"page":"107014","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Unlocking the benefits of allopurinol: the role of timely initiation and adherence in cardiovascular and renal outcomes in hyperuricemia"],"prefix":"10.1016","volume":"152","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0663-2733","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Inotai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00e1vid","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e1bor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e1ndor","family":"Kov\u00e1cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s","family":"D\u00f3czi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7846-0101","authenticated-orcid":false,"given":"Valerie","family":"Tikhonoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca Degli","family":"Esposti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zolt\u00e1n","family":"Kal\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8039-8781","authenticated-orcid":false,"given":"Claudio","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejim.2026.107014_bib0001","first-page":"3167","article-title":"Update on the epidemiology, genetics, and therapeutic options of hyperuricemia","volume":"12","author":"Li","year":"2020","journal-title":"Am J Transl Res"},{"issue":"2","key":"10.1016\/j.ejim.2026.107014_bib0002","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"},{"issue":"10287","key":"10.1016\/j.ejim.2026.107014_bib0003","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ejim.2026.107014_bib0004","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/HJH.0000000000003807","article-title":"Young Group of The Italian Society of Cardiovascular Prevention (SIPREC). Asymptomatic hyperuricemia: to treat or not a threat? A clinical and evidence-based approach to the management of hyperuricemia in the context of cardiovascular diseases","volume":"42","author":"Fiori","year":"2024","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2026.107014_bib0005","article-title":"Crystal clear - part I: the role of uric acid in cardiorenal disease","author":"Borghi","year":"2025","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.ejim.2026.107014_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.4078\/jrd.2024.0054","article-title":"The pathogenesis of gout","volume":"32","author":"Ahn","year":"2025","journal-title":"J Rheum Dis"},{"issue":"5","key":"10.1016\/j.ejim.2026.107014_bib0007","doi-asserted-by":"crossref","first-page":"312","DOI":"10.5114\/reum.2020.100140","article-title":"Pathophysiology of hyperuricemia and its clinical significance - a narrative review","volume":"58","author":"Skoczy\u0144ska","year":"2020","journal-title":"Reumatologia"},{"issue":"2","key":"10.1016\/j.ejim.2026.107014_bib0008","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11926-009-0022-4","article-title":"Quality of life and quality of care for patients with gout","volume":"11","author":"Singh","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.ejim.2026.107014_bib0009","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.maturitas.2018.10.012","article-title":"Gout - an update of aetiology, genetics, co-morbidities and management","volume":"118","author":"Robinson","year":"2018","journal-title":"Maturitas"},{"key":"10.1016\/j.ejim.2026.107014_bib0010","unstructured":"National Center for Public Health and Pharmacy [in Hungarian] NNGYK. Gy\u00f3gyszeradatb\u00e1zis. Milurit 100 mg tablet SmPC. https:\/\/ogyei.gov.hu\/gyogyszeradatbazis&action=show_details&item=15833 [Accessed 18 December 2025]."},{"key":"10.1016\/j.ejim.2026.107014_bib0011","unstructured":"National Center for Public Health and Pharmacy [in Hungarian] NNGYK. Gy\u00f3gyszeradatb\u00e1zis. Milurit 300 mg tablet SmPC. https:\/\/ogyei.gov.hu\/gyogyszeradatbazis&action=show_details&item=15834 [Accessed 23 \u00c1pril 2025]."},{"issue":"1","key":"10.1016\/j.ejim.2026.107014_bib0012","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40801-019-00174-7","article-title":"Severe cutaneous adverse drug reactions associated with allopurinol: an analysis of spontaneous reporting system in Southern Italy","volume":"7","author":"Scavone","year":"2020","journal-title":"Drugs Real World Outcomes"},{"issue":"8","key":"10.1016\/j.ejim.2026.107014_bib0013","article-title":"Colchicine for acute gout","volume":"8","author":"McKenzie","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2026.107014_bib0014","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.12659\/MSM.899852","article-title":"Hyperuricemia-related diseases and xanthine oxidoreductase (XOR) inhibitors: an overview","volume":"22","author":"Chen","year":"2016","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.ejim.2026.107014_bib0015","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3389\/fmed.2018.00160","article-title":"Physiology of hyperuricemia and urate-lowering treatments","volume":"5","author":"Benn","year":"2018","journal-title":"Front Med"},{"key":"10.1016\/j.ejim.2026.107014_bib0016","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s40292-018-0250-7","article-title":"Exploration into uric and cardiovascular disease: Uric Acid Right for Heart Health (URRAH) project. A study protocol for a retrospective observational study","volume":"25","author":"Desideri","year":"2018","journal-title":"High Blood Press Cardiovasc Prev"},{"issue":"4","key":"10.1016\/j.ejim.2026.107014_bib0017","doi-asserted-by":"crossref","first-page":"416","DOI":"10.23736\/S0031-0808.21.04357-3","article-title":"The URRAH study","volume":"63","author":"Del Pinto","year":"2021","journal-title":"Panminerva Med"},{"issue":"2","key":"10.1016\/j.ejim.2026.107014_bib0018","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/HYPERTENSIONAHA.119.13643","article-title":"from the Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension. Identification of the uric acid thresholds predicting an increased total and cardiovascular mortality over 20 years","volume":"75","author":"Virdis","year":"2020","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.ejim.2026.107014_bib0019","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/HJH.0000000000003319","article-title":"Working Group on Uric Acid and Cardiovascular Risk of the Italian Society of Hypertension (SIIA). Serum uric acid \/serum creatinine ratio as a predictor of cardiovascular events. Detection of prognostic cardiovascular cut-off values","volume":"41","author":"Casiglia","year":"2023","journal-title":"J Hypertens"},{"key":"10.1016\/j.ejim.2026.107014_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40292-023-00602-4","article-title":"The results of the URRAH (Uric Acid Right for Heart Health) project: a focus on hyperuricemia in relation to cardiovascular and kidney disease and its role in metabolic dysregulation","volume":"30","author":"Maloberti","year":"2023","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"10.1016\/j.ejim.2026.107014_bib0021","series-title":"Methods for the economic evaluation of health care programmes","author":"Drummond","year":"2015"},{"issue":"5","key":"10.1016\/j.ejim.2026.107014_bib0022","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1007\/s10067-015-3039-2","article-title":"\"You want to get on with the rest of your life\": a qualitative study of health-related quality of life in gout","volume":"35","author":"Chandratre","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"7","key":"10.1016\/j.ejim.2026.107014_bib0023","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/ijcp.12604","article-title":"Allopurinol adherence among patients with gout: an Italian general practice database study","volume":"69","author":"Mantarro","year":"2015","journal-title":"Int J Clin Pract"},{"key":"10.1016\/j.ejim.2026.107014_bib0024","unstructured":"Tutti per uno. L\u2019aderenza \u00e8 un gioco di squadra. https:\/\/fondazionecuore.it\/fipc\/tutti-per-uno\/ [Accessed 18 December 2025]."},{"key":"10.1016\/j.ejim.2026.107014_bib0025","unstructured":"Critical appraisal skills programme: how to use the PICO framework to aid critical appraisal https:\/\/casp-uk.net\/pico-framework\/ [Accessed 18 December 2025]."},{"issue":"1","key":"10.1016\/j.ejim.2026.107014_bib0026","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2026.107014_bib0027","unstructured":"The R project for statistical computing https:\/\/www.r-project.org\/ [Accessed 18 December 2025]."},{"issue":"3","key":"10.1016\/j.ejim.2026.107014_bib0028","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1161\/01.STR.22.3.312","article-title":"Probability of stroke: a risk profile from the Framingham study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"issue":"5","key":"10.1016\/j.ejim.2026.107014_bib0029","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/ndt\/gfv454","article-title":"An estimated glomerular filtration rate equation for the full age spectrum","volume":"31","author":"Pottel","year":"2016","journal-title":"Nephrol Dial Transplant"},{"issue":"10264","key":"10.1016\/j.ejim.2026.107014_bib0030","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1016\/S0140-6736(20)32234-0","article-title":"FAST Study Group. Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial","volume":"396","author":"Mackenzie","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ejim.2026.107014_bib0031","unstructured":"Drugs.com https:\/\/www.drugs.com\/ [Accessed 18 December 2025]."},{"key":"10.1016\/j.ejim.2026.107014_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejim.2026.106727","article-title":"Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2025 update","volume":"146","author":"Johnson","year":"2026","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.ejim.2026.107014_bib0033","unstructured":"Italian Medicines Agency - AIFA [in Italian] Agenzia Italiana del Farmaco. Allopurinolo (Mylan) 100\/300mg tablet SmPC. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/api.aifa.gov.it\/aifa-bdf-eif-be\/1.0.0\/organizzazione\/2322\/farmaci\/45054\/stampati%3Fts%3DRCP&ved=2ahUKEwjU1P_kopGUAxUdDRAIHX0FE-4QFnoECB4QAQ&usg=AOvVaw3Oxbv4q2CaZMrIqxQfATS8 [Accessed 23 April 2026]."},{"key":"10.1016\/j.ejim.2026.107014_bib0034","unstructured":"Italian Medicines Agency - AIFA [in Italian] Agenzia Italiana del Farmaco. Allopurinolo (Teva Italia) 100\/300mg tablet SmPC. https:\/\/www.google.com\/url?sa=t&source=web&rct=j&opi=89978449&url=https:\/\/api.aifa.gov.it\/aifa-bdf-eif-be\/1.0.0\/organizzazione\/813\/farmaci\/40180\/stampati%3Fts%3DRCP&ved=2ahUKEwjU1P_kopGUAxUdDRAIHX0FE-4QFnoECBgQAQ&usg=AOvVaw2hjTLXNMVrVTU77-XDj1-P [Accessed 23 April 2026]."},{"issue":"3","key":"10.1016\/j.ejim.2026.107014_bib0035","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s40258-016-0300-z","article-title":"How can pricing and reimbursement policies improve affordable access to medicines? lessons learned from European countries","volume":"15","author":"Vogler","year":"2017","journal-title":"Appl Health Econ Health Policy"},{"key":"10.1016\/j.ejim.2026.107014_bib0036","article-title":"Improvements in health-related quality of life with treat-to-target urate-lowering therapy in gout: a post hoc analysis of a randomized multicenter trial","author":"Barry","year":"2025","journal-title":"Arthritis Care Res"},{"issue":"1","key":"10.1016\/j.ejim.2026.107014_bib0037","doi-asserted-by":"crossref","first-page":"140","DOI":"10.3122\/jabfm.2022.01.210273","article-title":"To treat or not to treat? effect of urate-lowering therapy on renal function, blood pressure and safety in patients with asymptomatic hyperuricemia: a systematic review and network meta-analysis","volume":"35","author":"Tien","year":"2022","journal-title":"J Am Board Fam Med"},{"key":"10.1016\/j.ejim.2026.107014_bib0038","unstructured":"World Health Organisation: adherence to long-term therapies (2003) https:\/\/iris.who.int\/server\/api\/core\/bitstreams\/121c6b73-8651-442f-9560-e3b1d9c8a75c\/content [Accessed 23 April 2026]."},{"issue":"6","key":"10.1016\/j.ejim.2026.107014_bib0039","first-page":"483","article-title":"Statement ANMCO: acido urico e malattie cardiovascolari: evidenze e approccio terapeutico","volume":"24","author":"Di Fusco","year":"2023","journal-title":"G Ital Cardiol"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620526003195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:42:04Z","timestamp":1790840524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620526003195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":39,"alternative-id":["S0953620526003195"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107014","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unlocking the benefits of allopurinol: the role of timely initiation and adherence in cardiovascular and renal outcomes in hyperuricemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2026.107014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}],"article-number":"107014"}}